On Wednesday, in the course of current trade, Shares of Starbucks Corporation (NASDAQ:SBUX), dropped -0.51%, and is now trading at $55.45.
Starbucks Coffee Company, declared an additional commitment of $30 million as part of its Global Farmer Fund program, one aspect of the company’s comprehensive ethical sourcing initiatives that assist ensure the sustainability of the specialty coffee industry. This investment is the continuation of an initial $20 million commitment made in 2008, and distributed in partnership with leading lending organizations such as Root Capital and the Fairtrade Access Fund. To date, this financing has influenced more than 62 cooperatives in 8 countries benefiting more than 40,000 farmers.
“In 2015, we have achieved a number of milestones across our ethical sourcing initiatives but we know that the work isn’t done. This new investment demonstrates how we remain steadfast in our support of farmers around the world,” said Craig Russell, executive vice president of Global Coffee for Starbucks. “By providing access to capital, farmers have the ability to make planned investments in their infrastructure, offering the stability they need to manage ongoing complexities so that there is a future for them and the industry.”
Starbucks Corporation operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates in four segments: Americas; Europe, Middle East, and Africa; China/Asia Pacific; and Channel Development.
During an Afternoon trade, Shares of Receptos Inc (NASDAQ:RCPT), climbed 11.30%, and is now trading at $230.60.
Receptos Inc, declared the signing of a definitive merger agreement following which Celgene will acquire Receptos. Under the terms of the agreement, Receptos shareholders will receive $232.00 in cash for each share of Receptos common stock.
Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Its lead product comprises ozanimod, an oral therapy that is in phase III studies for the treatment of relapsing multiple sclerosis; and is in phase II studies to treat ulcerative colitis and crohn’s disease.
Finally, Array Biopharma Inc (NASDAQ:ARRY) , lost -2.67% Wednesday.
Array BioPharma, wholly-owned RAF inhibitor, encorafenib, was showcased on July 4 weekend at the 2015 ESMO World Congress of Gastrointestinal Cancer during an oral presentation. At the meeting, data were shared from a Phase 1b trial and preliminary data from a 100-patient randomized Phase 2 expansion of that trial testing the combination of encorafenib and cetuximab, an EGFR inhibitor, with or without the addition of alpelisib (BYL719) 1, an investigational PI3K inhibitor in patients with BRAF-mutant colorectal cancer (BRAFmut CRC). Results from the study indicate that these combinations can be administered with good tolerability and show promising clinical activity in this patient population with high unmet medical needs. Patient enrollment is now complete in the Phase 2 study.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
